AAAAAA

   
Results: 1-5 |
Results: 5
HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide
Authors: Di Leo, A Larsimont, D Gancberg, D Jarvinen, T Beauduin, M Vindevoghel, A Michel, J Focan, C Ries, F Gobert, P Closon-Dejardin, MT Dolci, S Rouas, G Paesmans, M Lobelle, JP Isola, J Piccart, MJ
Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
Authors: Piccart, MJ Di Leo, A Beauduin, M Vindevoghel, A Michel, J Focan, C Tagnon, A Ries, F Gobert, P Finet, C Closon-Dejardin, MT Dufrane, JP Kerger, J Liebens, F Beauvois, S Bartholomeus, S Dolci, S Lobelle, JP Paesmans, M Nogaret, JM
Citation: Mj. Piccart et al., Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J CL ONCOL, 19(12), 2001, pp. 3103-3110
Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13years update in a multicentre randomized trial
Authors: Focan, C Beauduin, M Salamon, E de Greve, J de Wasch, G Lobelle, JP Majois, F Tagnon, A Tytgat, J van Belle, S Vandervellen, R Vindevoghel, A
Citation: C. Focan et al., Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13years update in a multicentre randomized trial, BR J CANC, 85(1), 2001, pp. 1-8
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
Authors: Kvinnsland, S Anker, G Dirix, LY Bonneterre, J Prove, AM Wilking, N Lobelle, JP Mariani, O di Salle, E Polli, A Massimini, G
Citation: S. Kvinnsland et al., High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment, EUR J CANC, 36(8), 2000, pp. 976-982
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion
Authors: Focan, C Levi, F Kreutz, F Focan-Henrard, D Lobelle, JP Adam, R Dallemagne, B Jehaes, C Markiewicz, S Weerts, J Bismuth, H Jasmin, C Misset, JL
Citation: C. Focan et al., Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion, ANTI-CANC D, 10(4), 1999, pp. 385-392
Risultati: 1-5 |